Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206


Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.

Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM, Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R.

Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.


Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.

Yang F, Brown C, Buettner R, Hedvat M, Starr R, Scuto A, Schroeder A, Jensen M, Jove R.

Mol Cancer Ther. 2010 Apr;9(4):953-62. doi: 10.1158/1535-7163.MCT-09-0947. Epub 2010 Apr 6.


Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.

Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, DeClerck YA, Seeger R, Yu H, Jove R.

Cancer Biol Ther. 2012 May;13(7):534-41. doi: 10.4161/cbt.19603. Epub 2012 May 1.


Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways.

Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H.

Mol Cancer Res. 2010 Jan;8(1):35-45. doi: 10.1158/1541-7786.MCR-09-0220. Epub 2010 Jan 6.


Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.

Huang S, Sinicrope FA.

Mol Cancer Ther. 2010 Mar;9(3):742-50. doi: 10.1158/1535-7163.MCT-09-1004. Epub 2010 Mar 2.


Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.

Zhao W, Zhang T, Qu B, Wu X, Zhu X, Meng F, Gu Y, Shu Y, Shen Y, Sun Y, Xu Q.

Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.


Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.

Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.

World J Gastroenterol. 2011 Sep 14;17(34):3922-32. doi: 10.3748/wjg.v17.i34.3922.


Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.

Yang F, Jove V, Chang S, Hedvat M, Liu L, Buettner R, Tian Y, Scuto A, Wen W, Yip ML, Van Meter T, Yen Y, Jove R.

Cancer Biol Ther. 2012 Apr;13(6):349-57. doi: 10.4161/cbt.19239. Epub 2012 Apr 1.


Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.

Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.

Hepatology. 2009 Dec;50(6):1861-70. doi: 10.1002/hep.23214.


Sorafenib exerts anti-glioma activity in vitro and in vivo.

Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC.

Neurosci Lett. 2010 Jul 12;478(3):165-70. doi: 10.1016/j.neulet.2010.05.009. Epub 2010 May 12. Erratum in: Neurosci Lett. 2013 Feb 28;539:93.


Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.

Oh SJ, Erb HH, Hobisch A, Santer FR, Culig Z.

Endocr Relat Cancer. 2012 May 3;19(3):305-19. doi: 10.1530/ERC-11-0298. Print 2012 Jun.


Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.

Katz SI, Zhou L, Chao G, Smith CD, Ferrara T, Wang W, Dicker DT, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2406-16. Epub 2009 Dec 2.


The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

Niessner H, Beck D, Sinnberg T, Lasithiotakis K, Maczey E, Gogel J, Venturelli S, Berger A, Mauthe M, Toulany M, Flaherty K, Schaller M, Schadendorf D, Proikas-Cezanne T, Schittek B, Garbe C, Kulms D, Meier F.

J Invest Dermatol. 2011 Feb;131(2):468-79. doi: 10.1038/jid.2010.297. Epub 2010 Oct 14.


Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.

Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.

Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518.


Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.

Chai H, Luo AZ, Weerasinghe P, Brown RE.

Int J Clin Exp Pathol. 2010 Apr 23;3(4):408-15.


Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.

Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.

J Hepatol. 2011 Nov;55(5):1041-8. doi: 10.1016/j.jhep.2011.01.047. Epub 2011 Feb 24.


Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.

Peng CL, Guo W, Ji T, Ren T, Yang Y, Li DS, Qu HY, Li X, Tang S, Yan TQ, Tang XD.

Cancer Biol Ther. 2009 Sep;8(18):1729-36. Epub 2009 Sep 6.


Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.

Cancer Res. 2006 Dec 15;66(24):11851-8.


Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.

Jane EP, Premkumar DR, Pollack IF.

J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. Epub 2006 Sep 7.


Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.

Sugiyama H, Onuki K, Ishige K, Baba N, Ueda T, Matsuda S, Takeuchi K, Onodera M, Nakanuma Y, Yamato M, Yamamoto M, Hyodo I, Shoda J.

J Gastroenterol. 2011 Jun;46(6):779-89. doi: 10.1007/s00535-011-0380-3. Epub 2011 Feb 18.

Items per page

Supplemental Content

Write to the Help Desk